Nail in Medical Technology

NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy

... through the skin that surrounds the entire nail plate, according to a study conducted by ... The data represent a unique approach to treating nail fungus (onychomycosis), which resists topical therapies because they cannot penetrate the nail and access the site of infection. The results ...

MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis

... the protocol as an increase in uninvolved (clear) nail area. While none of the 37 patients reached all ... added, "If we exclude 6 patients whose baseline nail involvement in my opinion was too severe to ... things, more clearly define resolved fungal nail infection ...

NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis

... adequate time for subjects to grow out a clear nail after successfully treating the infection will ... trial to complete the 24 week assessment of clear nail growth. Final results will be available in the ... its effect locally by penetrating to reach the nail bed where dermatophytes responsible for ...

NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008

... (cold sores) and onychomycosis (toe nail fungus) at the annual meeting of the American ... concerns. Initial results in subjects with toe nail fungus indicate an excellent safety profile with ... the skin and diffusing laterally underneath the nail plate to reach the dermatophytes and kill both ...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis

... and sustained improvements in skin and nail psoriatic disease (as measured by a 75 percent ... with psoriasis of at least three percent, and the nail Psoriasis Severity Index [NAPSI]). Golimumab, ... 100 also experienced improvements in nail psoriasis as measured by NAPSI and these ...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... psoriasis. Of these, about one in 14 will develop PsA. It is frequently associated with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness and tenderness of the joints and surrounding tissue and reduced range of motion. Joints of the hands, ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... that can lead to joint destruction and debilitation. It is frequently associated with inflamed, scaly, red patches of skin psoriasis and psoriasis nail involvement. Symptoms may include stiffness and tenderness of the joints and surrounding tissue and reduced range of motion. Joints of the hands, ...

NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection

... work to date strongly suggests that NVC-422 may be a potent and well-tolerated treatment for numerous serious skin infections such as acne, nail fungus and topical viral infections, where antibiotics are not effective. Advancing NVC-422 into Phase II clinical trials reinforces the strength of ...

Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis

... health of skin with an extensive line of products across the world that treat a range of dermatological conditions including: acne, rosacea, fungal nail infections, psoriasis & steroid-responsive dermatoses, pigmentary disorders, medical solutions for skin senescence and skin cancers. With a ...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... applied econazole lacquer based on Access' proprietary SEPA polymer technology, for the treatment of onychomycosis, a condition commonly known as nail fungus. Thiarabine is a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For ...

Lytix Presents LTX-109 Anti-Microbial Data at ICAAC

... that although the initial formulation is for the treatment of skin infections, we could now consider it for other indications such as skin and nail fungal infections, acne and oropharyngeal candidaisis. We are now in the final stages of preclinical development and look forward to taking LtX-109 ...

Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections

... -- Keraderm, a leader in the development of phototherapy treatments for infections, plans to introduce a $100 phototherapy treatment for fungal nail infections (onychomycosis) in 2009 upon completion of their current pivotal trials and pending marketing clearance from the FDA. "Our goal," states ...

Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients

... is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. Anacor entered into a worldwide license, development and commercialization agreement for AN2690 with Schering-Plough for all indications ...

MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection

... and pexiganan. EcoNail is a topically applied SEPA- based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. We recently acquired exclusive worldwide license rights to pexiganan, a novel topical anti-infective for the treatment of diabetic foot ...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

... vomiting, hair loss, rash, infusion-site reactions, odd sensations (such as numbness, tingling, or burning) or weakness in the hands and feet, nail changes, muscle and/or bone pain, or excessive tearing. Because of the potential risk of fetal harm, pregnant women should not receive Taxotere(R). ...

MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera

... completed two Phase 3 clinical trials and that fits our strategic focus and complements our lead product candidate, EcoNail(R) for treatment of nail fungus," stated Robert J. DeLuccia, President and CEO of MacroChem. "Both drugs would treat diseases of the foot predominantly treated by the same ...

ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study

... including S. aureus sepsis and abscesses requiring incision and drainage were reported. Sun exposure may exacerbate these effects. A related nail disorder, occurring in 12% (0.4% Grade 3) of patients, was characterized as a paronychial inflammation. The safety of ERBITUX in combination with ...

Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... S. aureus sepsis and abscesses requiring incision and drainage were reported. Sun exposure may exacerbate these effects. A related nail disorder, occurring in 12% (0.4% Grade 3) of patients, was characterized as a paronychial inflammation. The safety of ERBITUX in combination with ...

Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer

... S. aureus sepsis and abscesses requiring incision and drainage were reported. Sun exposure may exacerbate these effects. A related nail disorder, occurring in 12% (0.4% Grade 3) of patients, was characterized as a paronychial inflammation. The safety of ERBITUX in combination with ...

Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer

... S. aureus sepsis and abscesses requiring incision and drainage were reported. Sun exposure may exacerbate these effects. A related nail disorder, occurring in 12% (0.4% Grade 3) of patients, was characterized as a paronychial inflammation. The safety of ERBITUX in combination with ...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

... S. aureus sepsis and abscesses requiring incision and drainage were reported. Sun exposure may exacerbate these effects. A related nail disorder, occurring in 12% (0.4% Grade 3) of patients, was characterized as a paronychial inflammation. The safety of ERBITUX in combination with ...

Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting

... S. aureus sepsis and abscesses requiring incision and drainage were reported. Sun exposure may exacerbate these effects. A related nail disorder, occurring in 12% (0.4% Grade 3) of patients, was characterized as a paronychial inflammation. The safety of ERBITUX in combination with ...

MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy

... and inflammatory skin diseases and conditions. The Company’s major efforts are focused on projects targeting Raynaud’s phenomenon, nail psoriasis and actinic keratosis. In addition to historical facts or statements of current condition, this press release contains forward-looking ...

NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product

... (terbinafine), formulated with terbinafine and the Company's patented NexACT permeation enhancer, which facilitates the delivery of the drug into the nail bed, where the fungus resides. About NexMed NexMed, Inc. is an emerging drug developer that is leveraging its proprietary drug technology to ...

Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

... S. aureus sepsis and abscesses requiring incision and drainage were reported. Sun exposure may exacerbate these effects. A related nail disorder, occurring in 12% (0.4% Grade 3) of patients, was characterized as a paronychial inflammation. The safety of ERBITUX in combination with ...